What stages did Erdafitinib go through from R&D to launch?

Erdafitinib is an oral kinase inhibitor that targets FGFR (fibroblast growth factor receptor) mutations and is mainly used to treat urothelial cancer with FGFR gene alterations. It has gone through multiple key stages from research and development to launch, embodying a model of modern precision medicine drug development. First of all, drug research and development begins with an in-depth understanding of the mechanism of the FGFR signaling pathway in tumor development and development. Through high-throughput screening and structural optimization, scientists designed erdafitinib, a small molecule compound that can selectively inhibit the tyrosine kinase activity of FGFR1-4 and block the proliferation and survival signals of tumor cells.

Subsequently, erdafitinib entered the preclinical research stage, including experiments on pharmacology and toxicology, safety evaluation, and pharmacokinetics, to provide scientific basis for subsequent clinical trials. Preclinical data show that erdafitinib has significant effects in inhibiting FGFR mutation tumor models and has a good safety profile, supporting its entry into human trials. Subsequently, a series of clinical trials were carried out, divided into phases I, II and III. Early phase I trials mainly evaluate the safety, tolerability and preliminary efficacy of the drug to provide a basis for dosage selection and usage. Phase II trials focus on specific tumor patient groups to verify efficacy and safety.

Following the positive results from thePhase II trial, the pharmaceutical company promoted the pivotal Phase III clinical study to confirm its efficacy and safety in treating urothelial cancer. Based on these data, erdafitinib received accelerated approval from the US FDA in 2019, becoming the first oral targeted drug approved for the treatment of urothelial cancer with FGFR gene alterations. Subsequently, the drug was approved in many countries and entered the market. After marketing, the efficacy and safety of the drug continue to be evaluated through real-world data and follow-up clinical studies to optimize patient use.

In general, the R&D and marketing process of erdafitinib reflects the complete process of modern precision tumor treatment drugs from target discovery, drug design, clinical verification to regulatory approval. It not only brings new treatment options to patients with FGFR mutation-related cancers, but also promotes continuous progress in the field of targeted therapy. In the future, with the study of more indications and the exploration of combination drug regimens, erdafitinib is expected to play a greater role in tumor treatment.

Reference materials:https://www.drugs.com